2017 M&A outlook for mid-market pharma: dealmaking will continue to be a key growth strategy

In an expert view piece, Michael Jewell, healthcare partner at Cavendish Corporate Finance, explains why we can expect significant M&A activity in the pharma, health care and biotech sectors to shape 2017.

This year is shaping to be another strong year for pharma M&A, with forecasts that the high level of activity seen in recent years will continue to trend upwards in 2017.

As market conditions remain volatile and competition in the sector increases, incentives for pharma companies in the mid-market to pursue the M&A route are abundant.